InterCure Ltd. (INCR)
| Previous Close | 2.6500 |
| Open | 2.6300 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.6300 - 2.7000 |
| 52 Week Range | 0.9900 - 2.9200 |
| Volume | |
| Avg. Volume | 86,020 |
| Market Cap | 121.223M |
| Beta (5Y Monthly) | 0.24 |
| PE Ratio (TTM) | 22.17 |
| EPS (TTM) | 0.1200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 33.99 |
Business WireInterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million
NEW YORK & HERZLIYA, Israel, April 01, 2024--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced preliminary results for the full year of 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted.
Business WireInterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint
NEW YORK & HERZLIYA, Israel, March 22, 2024--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company outside of North America, is thrilled to congratulate The Federal Republic of Germany for the passing of the "CannG" Cannabis Act, which is expected to take effect on April 1, 2024. On the backdrop of this monumental development, InterCure expects to launch a series of products in Germany in the coming months.
GlobeNewswireInterCure Provides an Update Regarding Nir Oz Facility
NEW YORK, and HERZLIYA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company’s press release issued on October 17, 2023, in which the Company provided an update regarding the status of the security situation in Israel, and its impact on the Company and its employees, the Company is providing an additi
